S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalent, Inc. stock logo
CTLT
Catalent
$55.77
-0.3%
$56.85
$31.45
$60.20
$10.09B1.22.59 million shs1.06 million shs
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$6.73
+3.5%
$6.88
$4.14
$9.37
$2.66B1.421.56 million shs591,168 shs
Hologic, Inc. stock logo
HOLX
Hologic
$75.10
+0.2%
$75.68
$64.02
$87.88
$17.63B11.81 million shs1.58 million shs
Insulet Co. stock logo
PODD
Insulet
$164.73
-0.9%
$175.14
$125.82
$335.91
$11.53B0.98874,858 shs589,071 shs
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$24.01
+0.3%
$26.49
$21.52
$33.08
$10.49B0.73966,250 shs1.44 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalent, Inc. stock logo
CTLT
Catalent
+0.30%-1.89%-0.04%+14.82%+32.94%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
-0.31%-7.14%-1.07%0.00%+12.85%
Hologic, Inc. stock logo
HOLX
Hologic
-0.25%-3.47%-1.87%+1.86%-9.20%
Insulet Co. stock logo
PODD
Insulet
-3.73%-6.28%-3.16%-18.46%-48.25%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
+0.57%-1.77%-10.31%-14.74%-19.39%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Catalent, Inc. stock logo
CTLT
Catalent
3.324 of 5 stars
1.14.00.04.63.20.81.9
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
3.242 of 5 stars
4.20.00.00.01.71.71.9
Hologic, Inc. stock logo
HOLX
Hologic
4.654 of 5 stars
3.24.00.04.21.92.52.5
Insulet Co. stock logo
PODD
Insulet
4.6907 of 5 stars
3.43.00.04.92.40.83.1
Smith & Nephew plc stock logo
SNN
Smith & Nephew
3.0028 of 5 stars
0.05.02.50.03.60.01.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Catalent, Inc. stock logo
CTLT
Catalent
2.15
Hold$52.46-5.94% Downside
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
2.47
Hold$8.7830.43% Upside
Hologic, Inc. stock logo
HOLX
Hologic
2.44
Hold$87.0015.85% Upside
Insulet Co. stock logo
PODD
Insulet
2.80
Moderate Buy$243.2147.64% Upside
Smith & Nephew plc stock logo
SNN
Smith & Nephew
2.40
HoldN/AN/A

Current Analyst Ratings

Latest HOLX, SNN, GDRX, CTLT, and PODD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Weight ➝ Overweight$9.00
4/10/2024
Hologic, Inc. stock logo
HOLX
Hologic
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00
4/4/2024
Catalent, Inc. stock logo
CTLT
Catalent
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$63.50
4/4/2024
Hologic, Inc. stock logo
HOLX
Hologic
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetIn-Line ➝ In-Line$76.00 ➝ $78.00
4/3/2024
Hologic, Inc. stock logo
HOLX
Hologic
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$80.00 ➝ $95.00
3/25/2024
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$7.50 ➝ $10.00
3/1/2024
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$6.00 ➝ $7.50
3/1/2024
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$5.00 ➝ $8.00
3/1/2024
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$7.00 ➝ $8.00
3/1/2024
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$6.50 ➝ $7.50
3/1/2024
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$12.00 ➝ $14.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Catalent, Inc. stock logo
CTLT
Catalent
$4.28B2.36$3.24 per share17.19$25.58 per share2.18
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$750.27M3.54$0.43 per share15.79$1.93 per share3.49
Hologic, Inc. stock logo
HOLX
Hologic
$4.03B4.37$5.34 per share14.07$20.48 per share3.67
Insulet Co. stock logo
PODD
Insulet
$1.70B6.80$3.62 per share45.51$10.49 per share15.70
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$5.55B1.89$3.24 per share7.40$11.94 per share2.01

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Catalent, Inc. stock logo
CTLT
Catalent
-$256M-$6.80N/A46.876.02-29.91%-2.43%-0.98%6/10/2024 (Estimated)
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
-$8.87M-$0.02N/A21.713.57-1.18%2.45%1.25%5/9/2024 (Confirmed)
Hologic, Inc. stock logo
HOLX
Hologic
$456M$2.1135.5917.192.5412.98%18.91%10.47%5/2/2024 (Confirmed)
Insulet Co. stock logo
PODD
Insulet
$206.30M$2.9156.6142.573.1112.16%32.19%7.93%5/9/2024 (Confirmed)
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$263MN/A0.0011.541.28N/AN/AN/AN/A

Latest HOLX, SNN, GDRX, CTLT, and PODD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$0.0870N/A-$0.0870N/AN/AN/A  
5/9/2024N/A
Insulet Co. stock logo
PODD
Insulet
$0.39N/A-$0.39N/AN/AN/A  
5/2/2024N/A
Hologic, Inc. stock logo
HOLX
Hologic
$0.98N/A-$0.98N/AN/AN/A  
2/29/2024Q4 2023
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$0.02$0.02N/A$0.10$195.59 million$196.64 million
2/22/2024Q4 2023
Insulet Co. stock logo
PODD
Insulet
$0.67$1.40+$0.73$1.36$461.26 million$509.80 million    
2/9/202412/31/2023
Catalent, Inc. stock logo
CTLT
Catalent
-$0.02-$0.24-$0.22$0.46$1.01 billion$1.03 billion    
2/1/2024Q1 24
Hologic, Inc. stock logo
HOLX
Hologic
$0.95$0.98+$0.03$0.93$989.32 million$1.01 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Catalent, Inc. stock logo
CTLT
Catalent
N/AN/AN/AN/AN/A
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
N/AN/AN/AN/AN/A
Hologic, Inc. stock logo
HOLX
Hologic
N/AN/AN/AN/AN/A
Insulet Co. stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$0.903.75%N/AN/A1 Years

Latest HOLX, SNN, GDRX, CTLT, and PODD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/4/2024
Smith & Nephew plc stock logo
SNN
Smith & Nephew
semi-annual$0.46202.8%4/1/20244/2/20245/22/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Catalent, Inc. stock logo
CTLT
Catalent
1.34
2.48
1.73
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
0.85
7.12
7.12
Hologic, Inc. stock logo
HOLX
Hologic
0.55
3.89
3.18
Insulet Co. stock logo
PODD
Insulet
1.86
3.51
2.62
Smith & Nephew plc stock logo
SNN
Smith & Nephew
0.44
1.77
0.72

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Catalent, Inc. stock logo
CTLT
Catalent
N/A
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
63.77%
Hologic, Inc. stock logo
HOLX
Hologic
94.73%
Insulet Co. stock logo
PODD
Insulet
N/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
25.64%

Insider Ownership

CompanyInsider Ownership
Catalent, Inc. stock logo
CTLT
Catalent
0.31%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
1.37%
Hologic, Inc. stock logo
HOLX
Hologic
1.75%
Insulet Co. stock logo
PODD
Insulet
0.90%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
1.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Catalent, Inc. stock logo
CTLT
Catalent
17,800180.97 million180.18 millionOptionable
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
694395.00 million389.59 millionOptionable
Hologic, Inc. stock logo
HOLX
Hologic
6,990234.73 million230.62 millionOptionable
Insulet Co. stock logo
PODD
Insulet
3,00070.02 million69.39 millionOptionable
Smith & Nephew plc stock logo
SNN
Smith & Nephew
18,452437.16 million432.79 millionOptionable

HOLX, SNN, GDRX, CTLT, and PODD Headlines

SourceHeadline
Smith & Nephew UK Ltd: Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressings role in pressure injury preventionSmith & Nephew UK Ltd: Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing's role in pressure injury prevention
finanznachrichten.de - April 18 at 8:01 AM
Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury preventionSmith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention
markets.businessinsider.com - April 18 at 8:01 AM
Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury preventionSmith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention
finance.yahoo.com - April 18 at 8:01 AM
Raymond James & Associates Sells 511,426 Shares of Smith & Nephew plc (NYSE:SNN)Raymond James & Associates Sells 511,426 Shares of Smith & Nephew plc (NYSE:SNN)
marketbeat.com - April 18 at 4:08 AM
London & Capital Asset Management Ltd Purchases Shares of 38,622 Smith & Nephew plc (NYSE:SNN)London & Capital Asset Management Ltd Purchases Shares of 38,622 Smith & Nephew plc (NYSE:SNN)
marketbeat.com - April 15 at 11:28 AM
Short Interest in Smith & Nephew plc (NYSE:SNN) Declines By 17.5%Short Interest in Smith & Nephew plc (NYSE:SNN) Declines By 17.5%
americanbankingnews.com - April 15 at 6:30 AM
Smith & Nephew plc (NYSE:SNN) Sees Large Drop in Short InterestSmith & Nephew plc (NYSE:SNN) Sees Large Drop in Short Interest
marketbeat.com - April 13 at 7:42 AM
Smith+Nephew (SNN) Expands in Australia With New AllianceSmith+Nephew (SNN) Expands in Australia With New Alliance
zacks.com - April 11 at 10:16 AM
Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in AustraliaSmith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia
globenewswire.com - April 8 at 6:00 PM
Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
finance.yahoo.com - April 4 at 1:20 PM
Smith+Nephews PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)Smith+Nephew's PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
globenewswire.com - April 4 at 11:13 AM
Smith+Nephew launches wound therapy system in USSmith+Nephew launches wound therapy system in US
msn.com - April 2 at 5:15 PM
Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic woundsSmith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
globenewswire.com - April 1 at 8:00 AM
Smith & Nephew plc (NYSE:SNN) Given Consensus Rating of "Moderate Buy" by BrokeragesSmith & Nephew plc (NYSE:SNN) Given Consensus Rating of "Moderate Buy" by Brokerages
marketbeat.com - March 29 at 2:29 AM
European Equities Traded in the US as American Depositary Receipts Slightly Higher ThursdayEuropean Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday
msn.com - March 28 at 12:11 PM
Smith & Nephew CFO designate John Rogers to start next weekSmith & Nephew CFO designate John Rogers to start next week
lse.co.uk - March 28 at 7:10 AM
Smith & Nephew: John Rogers Appointed CFOSmith & Nephew: John Rogers Appointed CFO
marketwatch.com - March 28 at 7:10 AM
Smith+Nephew: John Rogers To Join Board As Executive Director And CFO On 1 AprilSmith+Nephew: John Rogers To Join Board As Executive Director And CFO On 1 April
finanznachrichten.de - March 28 at 7:10 AM
Medical supplies firm Smith & Nephew teams up with mixed martial arts promoter the UFCMedical supplies firm Smith & Nephew teams up with mixed martial arts promoter the UFC
msn.com - March 25 at 7:16 PM
Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology PartnerSmith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
globenewswire.com - March 25 at 8:00 AM
Scharf Investments LLC Has $81.30 Million Holdings in Smith & Nephew plc (NYSE:SNN)Scharf Investments LLC Has $81.30 Million Holdings in Smith & Nephew plc (NYSE:SNN)
marketbeat.com - March 21 at 8:54 PM
Smith & Nephew: Scepticism has been overplayed, says leading investment bankSmith & Nephew: Scepticism has been overplayed, says leading investment bank
proactiveinvestors.co.uk - March 11 at 10:25 AM
Smith & Nephew plc 2023 Q4 - Results - Earnings Call PresentationSmith & Nephew plc 2023 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 28 at 1:13 AM
Smith & Nephew reports Q4 resultsSmith & Nephew reports Q4 results
msn.com - February 27 at 8:46 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Catalent logo

Catalent

NYSE:CTLT
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
GoodRx logo

GoodRx

NASDAQ:GDRX
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
Hologic logo

Hologic

NASDAQ:HOLX
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Insulet logo

Insulet

NASDAQ:PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Smith & Nephew logo

Smith & Nephew

NYSE:SNN
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.